摘要
目的探讨沙库巴曲缬沙坦钠片(商品名:诺欣妥)治疗心力衰竭的效果。方法选取96例心力衰竭患者作为研究对象,随机分为对照组和观察组,每组48例。对照组患者给予马来酸依那普利片治疗,观察组患者给予沙库巴曲缬沙坦钠片治疗。对比两组治疗效果,心功能指标[左室射血分数(LVEF)、左室舒张末期内径(LVEDD)及左室收缩末期内径(LVESD)],肾功能指标[血清尿素氮(BUN)、血肌酐(SCr)和肾小球滤过率(eGFR)],血清指标[脑钠肽(BNP)、心肌肌钙蛋白I(cTnI)及超敏C反应蛋白(hs-CRP)]。结果观察组患者的总有效率93.75%高于对照组的77.08%,差异具有统计学意义(P<0.05)。治疗前,两组患者的LVEF、LVEDD、LVESD对比差异无统计学意义(P>0.05);治疗后,观察组患者的LVEF(43.19±3.13)%明显高于对照组的(36.64±3.82)%,LVEDD(52.15±2.54)mm、LVESD(42.31±0.32)mm均明显小于对照组的(57.71±2.94)、(46.42±0.51)mm,差异具有统计学意义(P<0.05)。治疗前,两组患者的BUN、SCr、eGFR水平对比差异无统计学意义(P>0.05);治疗后,观察组BUN(6.40±1.53)mmol/L、SCr(75.40±18.44)μmol/L均明显低于对照组的(7.17±1.35)mmol/L、(86.51±14.95)μmol/L,eGFR(88.31±14.32)ml/(min·1.73 m2)明显高于对照组的(81.42±15.98)ml/(min·1.73 m^(2)),差异具有统计学意义(P<0.05)。治疗前,两组患者的BNP、cTnI及hs-CRP水平对比差异无统计学意义(P>0.05);治疗后,观察组患者的BNP(522.41±48.37)ng/L、cTnI(0.30±0.07)μg/L及hs-CRP(16.24±10.14)mg/L均明显低于对照组的(689.45±50.25)ng/L、cTnI(0.40±0.08)μg/L及hs-CRP(28.19±10.27)mg/L,差异具有统计学意义(P<0.05)。结论心力衰竭患者采用沙库巴曲缬沙坦钠片治疗的效果确切,有助于促进患者心肾功能恢复,降低心肌损伤和炎症水平,值得推广应用。
Objective To explore the effect of sacubactril valsartan sodium tablets(trade name:Entresto)on patients with heart failure.Methods A total of 96 patients with heart failure were selected as research subjects and randomly divided into a control group and an observation group,with 48 cases in each group.The control group was treated with enalapril maleate tablets,and the observation group was treated with sacubactril valsartan sodium tablets.Comparison was made on therapeutic effects,cardiac function indicators[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD)and left ventricular endsystolic diameter(LVESD)],renal function indicators[blood urea nitrogen(BUN),serum creatinine(SCr)and estimated glomerular filtration rate(eGFR)],serum markers[brain natriuretic peptide(BNP),cardiac troponin I(cTnI)and hypersensitive C-reactive protein(hs-CRP)].Results The total effective rate of 93.75%in the observation group was higher than 77.08%in the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in LVEF,LVEDD and LVESD between the two groups(P>0.05).After treatment,LVEF of(43.19±3.13)%in the observation group was significantly higher than(36.64±3.82)%in the control group;and LVEDD of(52.15±2.54)mm and LVESD of(42.31±0.32)mm were significantly smaller than(57.71±2.94)and(46.42±0.51)mm in the control group.The difference was statistically significant(P<0.05).Before treatment,there was no significant difference in BUN,SCr and eGFR levels between the two groups(P>0.05).After treatment,BUN of(6.40±1.53)mmol/L and SCr of(75.40±18.44)μmol/L in the observation group were significantly lower than(7.17±1.35)mmol/L and(86.51±14.95)μmol/L in the control group;and eGFR of(88.31±14.32)ml/(min·1.73 m^(2))was significantly higher than(81.42±15.98)ml/(min·1.73 m2)in the control group.The difference was statistically significant(P<0.05).Before treatment,there was no significant difference in BNP,cTnI and hs-CRP levels b
作者
宁俊霞
NING Jun-xia(Department of Cardiology,First People's Hospital of Pingyuan County,Dezhou 253100,China)
出处
《中国实用医药》
2024年第3期85-88,共4页
China Practical Medicine
关键词
心力衰竭
沙库巴曲缬沙坦钠片
心功能指标
Heart failure
Sacubactril valsartan sodium tablets
Cardiac function indicators
